Scott M. Lippman - Concepedia

Author

Scott M. Lippman

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Carter, Hannah, J. Jack Lee, Jeff Myers, Lippman, Scott M., Menter, S E Benner, S Lippman, S M Lippman, S M. Lippman, S. Lippman

1.1K

Publications

64.1K

Citations

115

H-Index

253

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center University of California San Diego National Cancer Institute The University of Texas Health Science Center at San Antonio Fred Hutch Cancer Center

About

Scott M. Lippman is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, cancer research, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	62	185	18.9K
2	Health Sciences	22	28	3K
3	Public Health	19	21	2.6K
4	Engineering	7	7	1.2K
5	Natural Sciences	5	5	157

Scott M. Lippman

412

Publications

49.1K

Citations

101

H-Index

Page 1

	Year	Citations
The Molecular Taxonomy of Primary Prostate Cancer Adam Abeshouse, Jaeil Ahn, Rehan Akbani, Cell UrologyGenitourinary CancerMedicinePathologyPrimary Prostate Cancer	2015	3.1K
The Influence of Finasteride on the Development of Prostate Cancer Ian M. Thompson, Phyllis J. Goodman, Catherine M. Tangen, New England Journal of Medicine	2003	2.5K
Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter Ian M. Thompson, Donna K. Pauler, Phyllis J. Goodman, New England Journal of Medicine	2004	2.4K
Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers Scott M. Lippman, Eric A. Klein, Phyllis J. Goodman, JAMA	2008	2.1K
Vitamin E and the Risk of Prostate Cancer Eric A. Klein, Ian M. Thompson, Catherine M. Tangen, JAMA	2011	1.7K
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Edward S. Kim, Vera Hirsh, Tony Mok, The Lancet Non-small-cell Lung CancerMedicineMetronomic TherapyClinical TrialsBronchial Neoplasm	2008	1.2K
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance Lauren A. Byers, Lixia Diao, Jing Wang, Clinical Cancer Research	2012	1.1K
The BATTLE Trial: Personalizing Therapy for Lung Cancer Edward S. Kim, Roy S. Herbst, Ignacio I. Wistuba, Cancer Discovery	2011	867
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study Jason K. Sicklick, Shumei Kato, Ryosuke Okamura, Nature Medicine EngineeringTumor HeterogeneityPatient SelectionMedicinePersonalized Combination Therapy	2019	678
Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity Michael S. Ewer, Scott M. Lippman Journal of Clinical Oncology CardiomyopathyHeart FailureOncologyCumulative DoseCardiovascular Disease	2005	640

Page 1